UPDATE -- Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China
February 14, 2023 04:02 ET
|
Clover Biopharmaceuticals
--As part of China’s second booster campaign, Clover’s premium, broadly protective protein-based vaccine is now available in Zhejiang province with additional provinces and municipalities to follow in...
三叶草生物新冠疫苗加强针在中国上市
February 13, 2023 23:39 ET
|
三叶草生物制药有限公司
--作为中国第二剂次加强免疫接种的一部分，三叶草生物优质、且具有广泛保护效力的蛋白疫苗现已在浙江省上市，并将于2023年第一季度在其他省市上市-- 中国上海, Feb. 14, 2023 (GLOBE NEWSWIRE) --...
Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China
February 13, 2023 23:39 ET
|
Clover Biopharmaceuticals
--As part of China’s second booster campaign, Clover’s premium, broadly protective protein-based vaccine is now available in Zhejiang province with additional provinces and municipalities to follow in...
三叶草生物公布关于新冠疫苗商业上市和2023年战略重点
January 15, 2023 19:00 ET
|
三叶草生物制药有限公司
--在中国，三叶草生物预期从2023年第一季度开始启动新冠疫苗SCB-2019（CpG 1018/铝佐剂）在多个省市的商业上市，并预计年度加强针接种将为三叶草生物优质的、具有广泛保护的重组新冠病毒蛋白亚单位疫苗（CHO 细胞）提供重要且持续的长期市场机会-- --SCB-2019（CpG...
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
January 15, 2023 19:00 ET
|
Clover Biopharmaceuticals
-- China commercial launch in multiple provinces and municipalities expected to begin in Q1 2023, and Clover anticipates a significant and sustained long-term annual booster market for its premium,...
Clinical Infectious Diseases发表研究，三叶草生物新冠候选疫苗能减少新冠的家庭传播
November 30, 2022 05:28 ET
|
三叶草生物制药有限公司
--一项由三叶草生物和国际疫苗研究所合作进行的研究表明，与安慰剂组相比，SCB-2019（CpG 1018/铝佐剂）疫苗接种者的家庭接触者，新冠感染的可能性降低了84%-- --结果表明，通过减少家庭接触者的传播，以及之前证实的保护效力，接种SCB-2019有望帮助控制新冠在社区内的蔓延-- --SCB-2019是迄今为止在临床研究中实现前瞻性证明显著减少新冠病毒传播的疫苗之一-- ...
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
November 30, 2022 05:28 ET
|
Clover Biopharmaceuticals
-- The study, a collaboration between Clover and the International Vaccine Institute, showed that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household...
三叶草生物公布2022年公司业务重要里程碑
October 09, 2022 08:12 ET
|
三叶草生物制药有限公司
--三叶草生物首要的新冠候选疫苗SCB-2019（CpG 1018/铝佐剂）向中国国家药品监督管理局、欧洲药品管理局和世界卫生组织递交注册申请的工作取得重大进展，预计在2022年第四季度完成-- --新的数据显示，SCB-2019作为异源加强针相较于灭活疫苗表现更优，针对全球主导的奥密克戎 BA.5变异株亚型具有强劲的中和作用，并将新冠感染在家庭接触者中的传播率降低了84%-- ...
Clover Provides Update on 2022 Corporate Milestones
October 09, 2022 08:12 ET
|
Clover Biopharmaceuticals
-- Significant progress made on regulatory submissions to the China NMPA, the EMA, and the WHO for Clover’s lead COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), with completion anticipated in Q4...
Clover’s COVID-19 Vaccine Candidate Receives European Union GMP Certificate
September 20, 2022 04:43 ET
|
Clover Biopharmaceuticals
SHANGHAI, China, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic...